Aim immunotech announces publication of positive data from late-stage pancreatic cancer early access program (eap) in the cancers special issue: combination and innovative therapies for pancreatic cancer

Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an early access program (eap) approved by the inspectorate of healthcare in the netherlands at erasmus medical center

AIM Ratings Summary

AIM Quant Ranking